Zai Lab Ltd ADR
Closed
SectorHealthcare
23.47 -0.64
Overview
Share price change
24h
Min
22.32
Max
23.97
Income | 191K -51M |
|---|---|
Sales | 6.7M 106M |
EPS | -0.46 |
Profit margin | -47.808 |
Employees | 1,784 |
EBITDA | -2.1M -46M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +67.3% upside |
Next Earnings | 5 Nov 2026 |
|---|
Market Cap | 559M 2.6B |
|---|---|
Previous open | 24.11 |
Previous close | 23.47 |
Zai Lab Ltd ADR Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Zai Lab Ltd ADR Forecast
Price Target
By TipRanks
67.3% upside
12 Months Forecast
Average 39.333 USD 67.3%
High 45 USD
Low 36 USD
Based on 3 Wall Street analysts offering 12 month price targets forZai Lab Ltd ADR - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Zai Lab Ltd ADR
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.
